Medline (NASDAQ:MDLN) Receives $50.62 Consensus PT from Analysts

Shares of Medline (NASDAQ:MDLN) have been assigned an average rating of “Moderate Buy” from the twenty-nine research firms that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $50.6154.

A number of research analysts have commented on MDLN shares. Rothschild & Co Redburn set a $42.00 price target on shares of Medline in a research note on Monday, January 12th. Stifel Nicolaus set a $55.00 price objective on Medline in a research note on Wednesday, February 25th. Tigress Financial raised their target price on Medline from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Piper Sandler began coverage on Medline in a research note on Monday, January 12th. They issued an “overweight” rating and a $50.00 price target on the stock. Finally, BNP Paribas Exane assumed coverage on Medline in a research report on Monday, January 12th. They issued a “neutral” rating and a $38.00 price target on the stock.

Medline Stock Performance

MDLN opened at $42.62 on Friday. The business’s fifty day simple moving average is $44.72. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $50.88.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The firm’s revenue was up 14.8% on a year-over-year basis.

Institutional Trading of Medline

Several hedge funds have recently modified their holdings of the company. Carlyle Group Inc. acquired a new position in shares of Medline in the 4th quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in Medline during the 4th quarter valued at $4,179,591,000. Vanguard Group Inc. acquired a new stake in Medline during the 4th quarter valued at $793,278,000. Morgan Stanley bought a new position in Medline in the 4th quarter valued at $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline in the fourth quarter worth $620,937,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.